NantHealth and Allscripts Collabroate
News Mar 10, 2015
NantHealth and Allscripts will collaborate on the development and delivery of cutting-edge, precision medicine solutions directly to the point of care. The companies will introduce an integrated, evidence-based, personalized approach to healthcare solutions that includes actionable clinical data, enabling physicians to make informed decisions from complex genomic and proteomic analysis.
"Our goal is to enable physicians to make better, more informed decisions, provide best-in-class patient care and monitor the effectiveness and progress of treatment, using real-time clinical and pan-omic data never before available," said Dr. Patrick Soon-Shiong, founder and chief executive officer of NantHealth. "We look forward to working in partnership with the Allscripts team as the first major Clinical EMR vendor to take a major advancement towards the interoperability necessary to enable physicians and patients to stay engaged and active - before, during and after treatment - and enable the most appropriate, personalized intervention as early as possible."
Transforming Cancer Care
Research has shown that a physician's ability to make effective, evidence-based clinical decisions can improve by using specifically matched cancer protocols and drugs, delivered to the patient based on the individual's unique DNA, RNA and proteomic profile, and integrated with the patient's holistic clinical picture. For the first time, NantHealth and Allscripts can integrate these two aspects into a unique knowledge-based solution to significantly improve the way clinicians treat cancer.
Beginning with genomic (DNA) and transcriptome (RNA) sequencing, foundational data on how a patient is likely to respond to a specific treatment protocol will integrate with big data and data-mining-based computational analysis. These new NantHealth technologies will enable providers to determine the most accurate treatment option in today's complex world of genomically driven cancer care.
With this comprehensive view of the patient from all data sources, physicians can then use NantHealth's eviti solution, a comprehensive oncology decision support application that helps select the optimal protocol for patients and verifies their eligibility for it. The eviti platform empowers oncologists with real-time, actionable, evidence-based treatment and clinical trial information to help them make informed treatment decisions for their patients.
Managing Population Health
NantHealth can gather and monitor patient data via NantHealth's DeviceConX and Hbox, an industry leading medical device data integration solution that works at the point of care for clinicians or at home for the patient. Combined with critical clinical data from the physician's EMR and community data collected across the continuum of care, clinicians can proactively manage and monitor populations of patients over time and optimize their treatment. Clinicians can then identify all relevant outcomes, improvements and gaps in care, and make them available within the care providers' workflow regardless of their environment.
Together, physicians and patients will have the tools to stay engaged and active and provide necessary intervention as early as possible. Leveraging innovations in patient engagement, care coordination and disease management, NantHealth and Allscripts are creating the first fully comprehensive and integrated platform that will provide a transformation to the coordination and delivery of cancer care.
"We're working with NantHealth to create a game-changing platform for coordinated cancer care," Allscripts Chief Executive Officer Paul M. Black said. "Integrated patient information – from the molecular level and from the entire continuum of care – is a powerful tool to improve health care."
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE